Interim report
Page 1
Interim Report Q2 April - June 2026 Your Blood Your Signals Your Health Understand your health from within
Page 2
Qlife Holding AB I Interim report Q2 April- June 2026 2 Content Financial calendar Interim Report Q3 2026 11 November 2026 Interim Report Q4 2026 10 February 2027 Annual Report 2026 21 April 2027 Interim Report Q1 2027 12 May 2027 Annual General Meeting 26 May 2027 Interim Report Q2 2027 25 August 2027 Shareholder information Listing Nasdaq First North Growth Market, Stockholm Ticker share Qlife ISIN code SE0022574331 Q2 in brief 3 Letter from the CEO 3 The Egoo system 6 Share and ownership 11 Financial comments group, Q2 12 Financial comments group, H1 13 Financial comments parent company, H1 14 Additional information 15 Group Income statement 16 Balance sheet 17 Cash flow statement 18 Changes in equity 18 Parent company Income statement 19 Balance sheet 20 Cash flow statement 21 Changes in equity 21 Notes and accounting principles 22
Page 3
Qlife Holding AB I Interim report Q2 April- June 2026 3 Financial summary – second quarter 2026 • Revenue in the period amounted to kSEK 728 (104). Revenue from contracted feasibility study. • EBITDA for the period amounted to kSEK –4,720 (-4,899), and net loss kSEK –4,978 (-5,174) • The total cash flow in the second quarter amounted to kSEK -2,617 (-2,056). • Earnings per share before/after dilution for the quarter amounted to SEK -0.17 (-0.62), calculated on weighted average number of shares in the period. Apr-Jun Jan-Jun Jan-Dec Group - Key figures - kSEK 2026 2025 2026 2025 2025 Revenue 728 104 750 210 324 Total Operating expenses -5,448 -5,003 -10,623 -10,310 -18,438 EBITDA -4,720 -4,899 -9,873 -10,100 -18,114 Total cash flow -2,617 -2,056 2,627 -1,917 -1,298 Cash reserve 4,360 651 4,360 651 1,417 Shareholders equity 2,650 -5,511 2,650 -5,511 -7,508 Number of employees 2 2 2 2 2 Significant events – second quarter of 2026 • On 23 April Qlife informs that the Swedish Inspectorate of Strategic Products (“ISP”) has approved remaining shareholders related to the rights issue, the results of which were announced on 24 March 2026. The ISP has assessed that there is no reason to assume that the investments in question are foreign direct investments that could have a harmful effect on Sweden’s security or on public order or public safety in Sweden. The notifications are therefore left without action. • On 23 April the shareholders of Qlife Holding AB are invited to attend the Annual General Meeting on 27 May 2026 at the offices of Moll Wendén Advokatbyrå at Stortorget 8 in Malmö. • On 1 June 2026 Qlife announces that it has entered into a fully funded feasibility agreement with a global pharma company to test the feasibility on Egoo Health for a specific biomarker application. Significant events after the second quarter of 2026 • On 17 July 2026 Qlife provides business update for the first half of 2026. The company emphasises that it has diligently worked to advance multiple strategic partnership initiatives across both pharmaceutical and diagnostics sectors, while maintaining steady progress on its Egoo Health platform and regulatory milestones.
Page 4
Qlife Holding AB I Interim report Q2 April- June 2026 4 Building Momentum Through Partnerships and Innovation Letter from the CEO Revenue and Commercial Progress The first half of 2026 has been a period of solid progress for Qlife. During the second quarter, we secured and initiated a fully financed feasibility project with a global pharmaceutical company. This project is an important milestone for us. Not only does it provide revenue, but it also demonstrates that leading pharmaceutical companies see potential in the Egoo platform and its ability to bring testing and health monitoring closer to patients. More broadly, we have continued to move forward on several strategic initiatives across both the pharmaceutical and diagnostics sectors. At the same time, we have strengthened the technological, commercial, and regulatory foundations of our business. Together, these activities reflect growing interest in decentralized healthcare solutions and digital health technologies. Advancing Pharmaceutical Partnerships Our most important activity during the period has been the continued progression of the feasibility project with a global pharmaceutical company. The project is advancing according to plan, and the final deliveries are expected after the summer. Once completed, we look forward to discussing the possibility of expanding the collaboration into a broader next-stage project. We are also working with another global pharmaceutical company to explore a new application of the Egoo platform focused on long-term health monitoring. The goal is to combine data from several biomarkers measured over time to provide a clearer picture of an individual’s health status, treatment response, and overall health development as they age. Potential applications include metabolic health, weight management and healthy ageing. The rapid growth of GLP-1 therapies is creating increased demand for tools that can help patients and healthcare providers understand the broader health effects of treatment, beyond weight loss alone. We believe Egoo could play an important role by enabling convenient monitoring of relevant biomarkers directly from the home. These activities strengthen our belief that the future of diagnostics is not only about individual test results, but also about understanding how health changes over time and using that information to support better healthcare decisions. Expanding the Diagnostic Platform Alongside our pharmaceutical activities, we continue to expand the capabilities of the Egoo platform through strategic partnerships. Our collaboration with Hipro Biotechnology continues to develop according to plan, and discussions with potential partners around the Hipro A1 platform are progressing positively. These activities may help expand the range of tests that can be offered through Egoo in the future. We also continue validation activities related to three diagnostic assays covered by our previously announced collaboration framework. These initiatives are focused on important disease areas such as diabetes, heart failure and kidney disease, where regular monitoring can play an important role in improving patient outcomes. Our objective remains clear: to make Egoo increasingly valuable by expanding the range of clinically relevant tests available on the platform. Regulatory Progress Regulatory progress remains an important focus area. During the first half of the year, we remained on schedule in the IVDR certification process for Egoo PHE, our proof-of-concept immunodiagnostic application. Achieving certification would be an important milestone for the company and further demonstrate our ability to bring innovative home-testing solutions to market. It also strengthens our position as we continue discussions with both pharmaceutical and diagnostic partners. Building a Partnership-Driven Platform Healthcare is changing. More care is moving from hospitals and clinics into people’s homes, and there is increasing demand for solutions that help patients take a more active role in managing their health. We believe Egoo is well positioned to benefit from this trend. Our strategy is built around partnerships. Rather than building every opportunity ourselves, we work with pharmaceutical, diagnostic, and digital health companies that can help accelerate adoption of the platform and expand its use across multiple healthcare applications. Over time, we believe this approach can create value through increased platform usage, expanding test menus, and future digital health services built around health data and patient monitoring. Future Growth Opportunities Looking ahead, we see significant opportunities emerging at the intersection of diagnostics, digital health, chronic disease management, and healthy ageing. The increasing demand for personalized healthcare, combined with growing adoption of therapies such as GLP-1 treatments, is creating a need for better ways to monitor patient health over time. We believe Egoo has the potential to become an important tool in this evolving healthcare landscape by providing frequent, accessible, and actionable health insights outside traditional healthcare settings. As additional tests, applications, and partnerships are added to the platform, we believe the long-term value and commercial potential of the Egoo ecosystem will continue to grow. Thomas Warthoe
Page 5
Qlife Holding AB I Interim report Q2 April- June 2026 5 Looking Ahead As we enter the second half of 2026, several important initiatives continue to move forward. Our priorities remain: • Completing the ongoing pharmaceutical feasibility project and exploring a potential next-stage collaboration. • Expanding pharmaceutical partnerships focused on patient monitoring and therapy management. • Broadening the range of tests available on the Egoo platform. • Continuing progress toward IVDR certification of Egoo PHE. • Strengthening the commercial foundation for long-term platform adoption. While significant work remains ahead, we are encouraged by the progress achieved during the first half of the year. The increasing engagement from potential partners, combined with our continued regulatory and commercial progress, gives us confidence in the opportunities ahead. On behalf of the Board and management team, I would like to thank our shareholders, employees, partners, and stakeholders for their continued support and confidence in Qlife. Göteborg, 26 August 2026 Thomas Warthoe, CEO
Page 6
Qlife Holding AB I Interim report Q2 April- June 2026 6 From Blood Insight to Better Living By bringing advanced blood testing closer to the individual, we aim to support earlier intervention, more personalized care, and improved long-term health outcomes. Whether enabling chronic disease management, supporting healthy aging, or contributing to the next generation of precision medicine, our vision is simple: turning blood insights into meaningful actions that help people live healthier, longer, and better lives.
Page 7
Qlife Holding AB I Interim report Q2 April- June 2026 7 Transforming blood data into insightful information to guide smarter health choices By analyzing blood metrics thoroughly, individuals and healthcare professionals can make more informed decisions that improve overall wellness and prevent potential diseases. Leveraging advanced technology and data interpretation, the goal is to convert raw blood analysis into actionable health strategies tailored to each person’s unique needs, ultimately empowering better health outcomes and proactive care.
Page 8
Qlife Holding AB I Interim report Q2 April- June 2026 8 Our vision is to improve the lives of patients living with chronic diseases We believe that better health starts with better insight. By making blood testing simple, accessible, and available closer to the patient, we strive to empower individuals and healthcare providers with timely information that supports informed decisions and proactive care. Our ambition is to transform complex health data into meaningful insights that can help improve quality of life, support treatment optimization, and ultimately contribute to healthier, longer lives.
Page 9
Qlife Holding AB I Interim report Q2 April- June 2026 9 Your blood data, your quality of life Your blood contains a wealth of information about your health, providing insights that can help guide treatment decisions, monitor disease progression, and support preventive care. When this information is available at the right time, it can empower individuals to take a more active role in managing their health and well-being.
Page 10
Qlife Holding AB I Interim report Q2 April- June 2026 10 Lab-quality blood testing, empowering better lives By transforming complex diagnostic data into actionable information, we aim to empower individuals to better understand their health, support healthcare professionals in making informed decisions, and improve the management of chronic diseases. Our vision is a future where convenient access to trusted blood testing helps people take greater control of their health, leading to improved quality of life and better long-term outcomes.
Page 11
Qlife Holding AB I Interim report Q2 April- June 2026 11 Qlife Holdings shares (QLIFE) are listed at Nasdaq First North Growth Market, Stockholm since 2 March 2020 Share and sharecapital As per 30 June 2026, the company’s share capital is SEK 4,619,868.32 divided into 28,874,177 shares of the same class, with a par value of SEK 0.16. Warrants series TO7 As part of a loan agreement entered March 2025 Qlife has granted 1,250,000 warrants of series TO7 to the lenders. The warrants have a term of 24 months from the signing of this Agreement and give the Lender the right to subscribe for shares in Qlife at a fixed subscription price of SEK 4 per share. The warrants are not admitted for trading. Warrants series TO8 As part of the extended loan agreement entered August 2025 Qlife has granted 1,004,000 warrants of series TO8 to the lenders. The warrants have a term of 18 months from the signing of this Agreement and give the Lender the right to subscribe for shares in Qlife at a fixed subscription price of SEK 4 per share. The warrants are not admitted for trading. Warrants to the board of directors In July 2025, Qlife Holding AB issues a total of 375,000 Warrants to the company’s five board members as remuneration for board work. Subscription for shares by virtue the warrants of series 2025/2028 may be exercised during the period from 1 August 2028 to and including 30 September 2028 at SEK 2 per share. After exercise of all issued warrants, the number of shares in the com- pany will amount to 31,503,177. Share and ownership
Page 12
Qlife Holding AB I Interim report Q2 April- June 2026 12 Financial comments Group, Q2 April - June 2026 Financial result Revenue in the period amounted to kSEK 728 (104). Revenue from contracted feasibility study. Raw materials and consumables amounted to kSEK 53 (-285), which is changes in components and parts for devices and capsules used both for sales and development activities. Other external expenses amounted to kSEK -4,918 (-4,283). The cost increase in other external expenses is mainly driven by costs related to software development and costs of business consultants. Personnel costs for the period amounted to kSEK -525 (-435). As per 30 June 2026 Egoo Healths Aps had 2 (2) employees. Depreciation of equipment and capitalized development costs amounted to kSEK -318 (-318). Depreciation of development costs is made over 5 years. Net financial income and expenses amounted to kSEK 60 (43) is related to interest on bridge loans. Earnings before interest and tax (EBIT) for the period amounted to kSEK -5,038 (-5,217) and net loss kSEK -4,978 (-5,174).
Page 13
Qlife Holding AB I Interim report Q2 April- June 2026 13 Financial comments Group, H1 Fixed assets Capitalized development costs relate to accumulated product development costs including costs for patent preparation and application. At the end of the second quarter 2026 the capitalized development costs amounted to kSEK 3,974 (5,244) relating to acquired assets from subsidiary in Denmark. Future development will take place in close collaboration with the company’s Chinese partner. At the beginning of the year capitalized development cost was kSEK 4,609. Current assets Inventory amounted to kSEK 3,026 (2,847), consisting of finished goods and parts and components for instruments, capsules and reagents. Account receivables of kSEK 947 (60) is related to the sales in 2026 and 2025. Other receivables mainly consist of VAT receivable. Cash and cash equivalents amounted to kSEK 4,360 (651) at the end of June 2026. Equity Equity amounted to kSEK 2,650 (-5,511) at the end of June 2026. Shareholder’s equity is specified on page 17 – “Group – changes in equity” . Debts Long-term debt - kSEK 7,991 (8,391) consists of debt to the bankruptcy estate for the takeover of assets from the former company in Denmark Accounts payables - kSEK 610 (1,246) - debts to suppliers. Other liabilities - kSEK 946 (4,874) - is mainly loan to external credit provider. Cash flow The total cash flow amounted to kSEK 2,627 (-1,917) for the two first quarters of 2026. Cash flow from operations and changes in working capital amounted to kSEK -11,980 (-9,192). Cash flow from investing activities amounted to kSEK 0 (0). Cash flow from financing activities is positive kSEK 14,607 (7,275) related to capital injections. Cash and cash equivalents are specified on page 17 – “Group – Consolidated Cash Flow statement” .
Page 14
Qlife Holding AB I Interim report Q2 April- June 2026 14 Financial comments Parent company, H1 January - June, H1 2026 Financial result Revenue amounted to kSEK 700 (700) in the period and consists of management fee from subsidiary. Other external cost consists of various administrative cost. Net financial income and expenses kSEK -121 (-503) is related to interest on bridge loans. Net loss for the period amounted to kSEK -7,434 (-6,896). Fixed assets Capitalized development costs - kSEK 3,973 (5,243). Fixed assets are shares in subsidiary Eego Health Aps kSEK 13,883 (5,328). Current assets Receivables from subsidiary kSEK 4,363 (4,335) is the outstanding loan to Egoo Health Aps Other receivables mainly consist of VAT reimbursement. Cash and cash equivalents amounted to kSEK 3,839 (362) at the end of June 2026 Equity Total equity amounted to kSEK 16,930 (1,164) end of June 2026. Shareholder’s equity is specified on page 20 – “Parent company – changes in equity” . Liabilities Long-term debt - kSEK 8,353 (8,699) consists of debt to the bankruptcy estate for the takeover of assets from the former company in Denmark Accounts payables - kSEK 361 (1,073) - debts to suppliers. Other liabilities - kSEK 664 (4,881) - is mainly loan to external credit provider. Cash flow The total cash flow amounted to kSEK 2,814 (-1,784) in first half of 2026. Cash and cash equivalents amounts to 3,839 (362) at the end of June 2026. Cash and cash equivalents are specified on page 20 – “Parent company – Cash Flow statement” .
Page 15
Qlife Holding AB I Interim report Q2 April- June 2026 15 Additional information Accounting principles Qlife Holding AB is following the IFRS reporting standard for its inte- rim financial reports. This Q2 interim financial report is the fourteenth interim report that has been prepared under the IFRS standard. The Group’s interim report is prepared in accordance with IAS 34 inte- rim reporting and the Swedish Accounting Act. The parent company’s interim report Is prepared in accordance with the Swedish Accounting Act and The Swedish Financial Reporting Board’s recommendation RFR 2 Reporting for Legal Entities. Risks and uncertainties Qlife Holding AB’s business is influenced by several factors which can- not be controlled by the Company at all or in part, and with possible effects on the Company’s earnings and financial position. In the assessment of the Company’s future operations, it is important, along- side the possibilities for growth in earnings, to also consider these risks. Risk factors include, among others, uncertainties with regards to validations and regulatory approvals, collaboration and partnerships, intellectual property issues, market and competition, manufacturing, purchasing and pricing, dependence on key persons and financial risks. Contact information Qlife Holding AB (publ) Ullevigatan 19 411 40 Göteborg Sweden www.qlifeholding.com Registration number 559224-8040 Thomas Warthoe, CEO Tel.: +45 21 63 35 34 tw@egoo.health Flemming Pedersen Chairman of the Board fp@bettercollective.com Certified advisor G&W Fondkommission Kungsgatan 3 111 43 Stockholm Sweden www.gwkapital.se Auditor Göteborgs Revision Lilla Bommen 1 411 02 Göteborg Mattias Olofson Authorised Public Accountant Statement by the Board of Directors The Board of directors and the CEO hereby affirm that the consolidated statement for the period January-June 2026 gives a true and fair representation of result, operations and financial position in Qlife Holding AB and the subsidiary Egoo Health ApS. Göteborg 26 August 2026 Board Flemming Pedersen Jørgen Drejer Chairman Board member Mikael Persson Jacob Glenting Board member Board member Lars Staal Wegner Board member CEO Thomas Warthoe This interim report has not been reviewed by the company’s auditor.
Page 16
Qlife Holding AB I Interim report Q2 April- June 2026 16 Financial overview, The Group Group - Consolidated Income Statement Apr-Jun Q2 Jan-Jun H1 Jan-Dec kSEK 2026 2025 2026 2025 2025 Revenue 728 104 750 210 324 Total operating income 728 104 750 210 324 Operating expenses Changes in inventories of finished goods -58 0 -69 -70 -70 Raw materials and consumables 53 -285 0 -576 -924 Other external expenses -4,918 -4,283 -9,616 -8,959 -15,451 Personnel costs -525 -435 -938 -705 -1,993 Total operating expenses -5,448 -5,003 -10,623 -10,310 -18,438 EBITDA -4,720 -4,899 -9,873 -10,100 -18,114 0 Amortization and depreciation -318 -318 -635 -635 -1,270 EBIT -5,038 -5,217 -10,508 -10,735 -19,384 Net financial income and expenses 60 43 -345 -489 -1,174 Result before tax -4,978 -5,174 -10,853 -11,224 -20,558 Tax 0 0 0 0 0 Net result for the period -4,978 -5,174 -10,853 -11,224 -20,558 Other comprehensive income Items that may be reclassified to result for the period. Foreign currency exchange gains and losses 0 0 0 0 0 Total comprehensive profit/loss for the period attributable to owner of Parent Company -4,978 -5,174 -10,853 -11,224 -20,558 Net result per share before and after dilution - SEK -0.17 -0.62 -0.38 -1.35 -1.31 Weighted average number of shares in the period before dilution 20,924,499 8,340,479 20,924,499 8,340,479 8,661,530 Total number af shares end of period 28,874,177 12,484,911 28,874,177 12,484,911 15,679,521
Page 17
Qlife Holding AB I Interim report Q2 April- June 2026 17 Financial overview, The Group Group - Consolidated Balance sheet kSEK 30 Jun 2026 30 Jun 2025 31 Dec 2025 ASSETS Intangible fixed assets Capitalized development costs 3,974 5,244 4,609 Total Intangible fixed assets 3,974 5,244 4,609 Tangible fixed assets Manufacturing equipment and fixtures 0 0 0 Total Tangible fixed assets 0 0 0 Total fixed assets 3,974 5,244 4,609 Current assets Inventory 3,026 2,847 3,021 Receivables Accounts receivables 947 60 19 Other receivables 210 286 183 Prepaid expenses and accrued income 42 308 383 Total receivables 1,199 654 585 Cash and cash equivalents 4,360 651 1,417 Total currents assets 8,585 4,152 5,023 TOTAL ASSETS 12,559 9,396 9,632 kSEK 30 Jun 2026 30 Jun 2025 31 Dec 2025 EQUITY AND LIABILITIES Equity Share Capital 4,620 1,998 2,509 Additional paid in capital 277,097 251,850 258,513 Retained earnings -289,853 -270,145 -279,316 Reserves 10,786 10,786 10,786 Total equity 2,650 -5,511 -7,508 Long term liabilities Loan from credit institution 7,991 8,391 8,132 Lease liabilities 0 0 0 Total long term liabilities 7,991 8,391 8,132 Short term liabilities Short term loans 362 308 6,308 Accounts payables 610 1,246 624 Other liabilities 946 4,874 2,000 Tax Liability 0 50 0 Accrued expenses and deferred income 0 38 76 Total short term liabilities 1,918 6,516 9,008 Total liabilities 9,909 14,907 17,140 TOTAL EQUITY AND LIABILITIES 12,559 9,396 9,632
Page 18
Qlife Holding AB I Interim report Q2 April- June 2026 18 Financial overview, The Group Group - Statement of changes in shareholders equity kSEK Share capital Other paid in capital Retained earnings Reserves Total shareholders equity Equity on 1 Jan 2025 1,130 245,443 -258,773 10,786 -1,414 Profit / Loss per 31 Dec 2025 -20,558 -20,558 Other comprehensive income 15 15 Total comprehensive income for the period 1,130 245,443 -279,316 10,786 -21,957 Transactions with owners Share Issue 1,379 16,682 18,061 Issurance costs -3,612 -3,612 Warrant programmes 0 0 Total Transactions with owners 1,379 13,070 0 0 14,449 Equity on 31 Dec 2025 2,509 258,513 -279,316 10,786 -7,508 Equity on 1 Jan 2026 2,509 258,513 -279,316 10,786 -7,508 Profit / Loss per 30 Jun 2026 -10,853 -10,853 Other comprehensive income 316 316 Total comprehensive income for the period 2,509 258,513 -289,853 10,786 -18,045 Transactions with owners Share Issue 2,111 23,906 26,017 Issurance costs -5,322 -5,322 Warrant programmes Total Transactions with owners 2,111 18,584 20,695 Equity on 30 Jun 2026 4,620 277,097 -289,853 10,786 2,650 Apr-Jun Q2 Jan-Jun H1 Jan-Dec kSEK 2026 2025 2026 2025 2025 Cash flow from operating activities Net loss before tax for the period -4,978 -5,174 -10,853 -11,224 -20,558 Depreciations and amortizations 318 318 635 635 1,270 Non-cash adjustments 0 28 0 0 15 Cash flow from operations before changes in working capital -4,660 -4,828 -10,218 -10,589 -19,273 Cash flow from changes in working capital Change in inventory 18 -313 -5 -15 -189 Change in receivables -366 -14 -611 -429 -360 Change in current payables -2,626 3,099 -1,146 1,841 -1,664 Cash flow from operating activities -7,634 -2,056 -11,980 -9,192 -21,486 Cash flow from investing activities Investments in intangible assets 0 0 0 0 0 Investments in tangible assets 0 0 0 0 0 Financial loss liquidated subsidiary 0 0 0 0 0 Cash flow from investing activities 0 0 0 0 0 Cash flow from financing activities Share issue / warrant program 5,120 0 26,017 10,848 18,061 Issuance costs 259 0 -5,322 -3,573 -3,613 Loans received/paid -362 0 -6,087 0 5,890 Down payments and interest 0 0 0 0 -150 Cash flow from financing activities 5,017 0 14,607 7,275 20,188 Total Cash flow in period -2,617 -2,056 2,627 -1,917 -1,298 Cash and cash equivalents at the period start 6,633 2,707 1,417 2,715 2,715 Foreign exchange difference 344 0 316 -147 0 Cash and cash equivalents at the period end 4,360 651 4,360 651 1,417 Group - Consolidated Cash Flow statement
Page 19
Qlife Holding AB I Interim report Q2 April- June 2026 19 Financial overview, The Parent Apr-Jun, Q2 Apr-Jun, Q2 Jan-Jun, H1 Jan-Dec kSEK 2026 2025 2026 2025 2025 Revenue 350 350 700 700 1,400 Raw materials and consumables 0 0 0 Other external costs -3,174 -2,726 -7,378 -6,458 -10,767 Personnel costs 0 0 0 0 0 Operating result -2,824 -2,376 -6,678 -5,758 -9,367 Depreciation -318 -318 -635 -635 -1,270 Net financial income and expenses 0 -37 -121 -503 -926 Loss before tax -3,142 -2,731 -7,434 -6,896 -11,563 Tax 0 0 0 0 0 Net loss for the period -3,142 -2,731 -7,434 -6,896 -11,563 Other comprehensive income 0 0 0 0 0 Total comprehensive profit/loss for the period attributable to owner of Parent Company -3,142 -2,731 -7,434 -6,896 -11,563 Parent company - Income Statement
Page 20
Qlife Holding AB I Interim report Q2 April- June 2026 20 5kSEK 30 Jun 2026 30 Jun 2025 31 Dec 2025 EQUITY and LIABILITIES Equity Restricted Equity Share Capital 4,620 1,998 2,509 Total Restricted Equity 4,620 1,998 2,509 Unrestricted Equity Share premium 331,252 365,606 312,670 Other paid in capital 178 178 178 Retained earnings -311,686 -359,723 -300,123 Profit / Loss -7,434 -6,895 -11,563 Total unrestricted Equity 12,310 -834 1,162 Total equity 16,930 1,164 3,671 Long term liabilities Other long term debt 8,353 8,699 8,495 Total long term liabilities 8,353 8,699 8,495 Short term liabilities Accounts payables 361 1,073 511 Short term loan 664 4,881 5,786 Other short term debt 2,000 Accrued expenses and deferred income 0 38 75 Total short term liabilities 1,025 5,992 8,372 Total liabilities 9,378 14,691 16,867 TOTAL EQUITY AND LIABILITIES 26,308 15,855 20,538 Parent company - Balance sheet Financial overview, The Parent kSEK 30 Jun 2026 30 Jun 2025 31 Dec 2025 ASSETS Immaterial fixed assets Balanced development 3,248 4,289 3,769 Patent 725 954 840 Total immaterial fixed assets 3,973 5,243 4,609 Financial fixed assets Shares in subsidiary 13,883 5,328 5,328 Total financial fixed assets 13,883 5,328 5,328 Total fixed assets 17,856 10,571 9,937 Current assets Recievables Receivables from subsidiary 4,363 4,335 9,010 Other receivables 208 285 183 Prepaid expenses and accrued income 42 302 383 Total receivables 4,613 4,922 9,576 Cash and cash equivalents 3,839 362 1,025 Total current assets 8,452 5,284 10,601 TOTAL ASSETS 26,308 15,855 20,538
Page 21
Qlife Holding AB I Interim report Q2 April- June 2026 21 Financial overview, The Parent Parent company - Statement of Cash Flow Parent company - Statement of changes in shareholders equity kSEK Share capital Share premium Other paid in capital Retained earnings Total shareholders equity Equity at 1 Jan 2025 1,130 359,199 178 -359,723 785 Profit / Loss per 31 Dec 2025 -11,562 -11,562 Adjustments previous years -59,599 59,599 0 Total comprehensive income for the period 1,130 299,600 178 -311,686 -10,778 Transactions with owners Share issue 1,379 16,682 18,061 Issuance cost -3,613 -3,613 Warrant programmes 225 Total transactions with owners 1,379 13,070 0 0 14,449 Equity at 31 Dec 2025 2,509 312,670 178 -311,686 3,671 Equity at 1 Jan 2026 2,509 312,670 178 -311,686 3,671 Profit / Loss per 30 Jun 2026 -7,434 -7,434 Other comprehensive income 0 Total comprehensive income for the period 2,509 312,670 178 -319,120 -3,764 Transactions with owners Share issue 2,111 23,906 26,017 Issuance cost -5,322 -5,322 Total Transactions with owners 2,111 18,584 0 0 20,695 Equity at 30 Jun 2026 4,620 331,252 178 -319,120 16,930 Apr-Jun, Q2 Apr-Jun, Q2 Jan-Jun, H1 Jan-Dec kSEK 2026 2025 2026 2025 2025 Cash flow from operating activities Profit / loss before tax -3,142 -2,731 -7,434 -6,896 -11,563 Financial loss from subsidiary 0 0 0 0 0 Non-cash adjustments 0 0 0 0 0 Depreciation 318 318 635 635 1,270 Other items 0 0 -141 0 0 Cash flow from operations before change in working capital -2,824 -2,413 -6,940 -6,261 -10,293 Cash flow from working activities 0 Change in receivables -1,746 -2,457 4,963 2,228 -340 Change in current payables -3,268 3,071 -7,348 302 -2,562 Cash flow from working activities -7,838 -1,799 -9,325 -3,731 -13,195 Cash flow from investing activities Loans to subsidiary 0 0 -8,555 -5,328 -7,416 Investment in subsidiary 0 0 0 0 0 Cash flow from investing activities 0 0 -8,555 -5,328 -7,416 Cash flow from financing activities Share issues 5,120 0 26,017 10,848 18,061 Issuance cost 259 0 -5,322 -3,573 -3,613 Warrants programmes 0 0 0 0 0 Loans received 0 0 0 0 5,193 Loans repaid 0 0 0 0 -149 Cash flow from financing activities 5,379 0 20,694 7,275 19,492 Total cash flow in period -2,459 -1,799 2,814 -1,784 -1,119 Cash and cash equivalents at period start 6,298 2,161 1,025 2,146 2,144 Cash and cash equivalents at period end 3,839 362 3,839 362 1,025
Page 22
Qlife Holding AB I Interim report Q2 April- June 2026 22 Notes GENERAL INFORMATION This interim report covers the Swedish parent company Qlife Holding AB (publ), corporate registration number 559224-8040, and its subsidiaries. The parent company is a limited liability company with its registered office in Göteborg, Sweden. The address of the main office is Ullevigatan 19, 411 40 Göteborg, Sweden. The main operation of the group is development and sales of the Egoo Systems and test capsules. The report for January to June 2026 was approved for publication on 26 August 2026, in accordance with a board decision on 26 August 2026. Note 2 Accounting principles This interim report for the group has been prepared in accordance with IAS 34 Interim Financial Reporting. The Group reporting of Qlife is based on International Financial Reporting Standards (IFRS) as adopted by the EU. The Group’s interim report is prepared in accordance with IAS 34 Interim Reporting and the Swedish Accounting Act. The parent company’s interim report is prepared in accordance with the Swedish Accounting Act and The Swedish Financial Reporting Board’s recommendation RFR 2 Reporting for Legal Entities. The first report under these standards was Q1 2022. Information according to IAS 34 Interim Reporting is given in notes as well as in other places in the interim report. Basis of preparation Group The Group applies International Financial Reporting Standards (IFRS) as endorsed by the EU Commission and interpretations of these (IFRIC). The Group also applies the Swedish Annual Accounts Act and the recommendation from the Swedish Financial Reporting Board, RFR 1, Supplementary accounting rules for groups. The consolidated financial reports are prepared in accordance with IFRS 1, First time adoption of International Financial Reporting Standards. This means that the Group has applied the same accounting principles, the principles that apply at the end of the period, in the report on the period’s opening financial position and during all periods reported in this report. The consolidated financial statements have been prepared in accordance with the acquisition value method. Parent Company The parent company financial statements are prepared in accordance with Annual Accounts Act and RFR 2 Accounting for Legal Entities. RFR 2 means that the report for the legal entity must apply all IFRSs and statements approved by the EU as far as possible within the framework of the Annual Accounts Act and regarding the connection between accounting and taxation. The recommendation states which exceptions and additions are to be made from IFRS. Previously, the Parent Company applied the Swedish Accounting Standards Board’s general advice 2012: 1 Annual Report and Consolidated Accounts (K3) and the Swedish Annual Accounts Act. The transition date to RFR 2 has been set to 1 January 2021, which means that the comparative figures for the financial year 2021 have been recalculated in accordance with RFR 2. New standards, interpretations, and amendments not yet effective There is a number of standards, amendments to standards, and interpretations which have been issued by the IASB that are effective in future accounting periods that the group has decided not to adopt early. None of these are expected to have a significant impact of the financial reports of the group. Consolidation Subsidiaries are all entities over which the group has control. Control exists when Qlife Holding AB is exposed to variability in returns from its investments in another entity and has the ability to affect those returns through its power over the other entity. Intragroup transactions and balances between the consolidated group undertakings are eliminated. The group undertakings are included in the consolidated accounts as from the date on which control is transferred to Qlife Holding AB and are no longer consolidated as from the date on which control ceases. Receivables and liabilities in foreign currencies The functional currency of the parent company and the reporting currency of the group is Swedish Kronor (SEK). Items in the financial reports of the different entities in the group are measured in the currency of the financial environment where each entity operates (functional currency). Transactions in foreign currencies are translated to the functional currency at the average rate for the period. Currency exchange gains and losses which arise on payment of those transactions and in translation of monetary assets and liabilities in foreign currency at closing rate, are recognized in the operating profit/loss. Foreign exchange gains and losses applicable to liabilities and cash are recognized as financial income or financial expense in the income statement. In the consolidation, assets and liabilities of foreign subsidiaries are translated at the closing rate. Revenue and expenses are translated at the average exchange rate for the reporting period. Foreign exchange rate differences are recognized as other comprehensive income, as part of the translation reserve. Segment information An operating segment is a part of a group that conducts operations from which it can generate revenue and incur costs and for which independent financial information is available. The group’s division into operating segments is in line with the internal reports that the group’s highest executive decisionmakers use to monitor operations and allocate resources between operating segments. The CEO is the group’s highest executive decision- maker. In Qlife, it is therefore the reports that the CEO receives on the results in different parts of the group that form the basis for the segment information. Note 1 General information
Page 23
Qlife Holding AB I Interim report Q2 April- June 2026 23 Revenue The group reports revenues from sales of goods. Revenue recognition is performed in accordance with the five-step model specified in IFRS 15. Revenue from sales of goods are recognized as revenue when control of the goods is transferred, which occurs when the goods are delivered to the customer. The revenue recognition of service takes place when the service has been delivered and in accordance with the current price list including any discounts specifically for the customer. Services that the group provides are recognized as revenue as the work is performed and reported in the period in which the work is performed. Grants that have been received before the conditions for the grant have been fulfilled are reported as liabilities. Grants are reported in accordance with IAS20 as a reduction of the capitalized expenses for development, in the same time period as the development work is carried out, and when the work is approved in accordance with the grant conditions. Financial items Interest income and interest expense are recognized in profit or loss by using the effective interest rate method. Financial expense is comprised of interest and other financing expenses. Employee benefits Employee benefits such as salaries and social expenses, paid vacation and paid sick leave are recognized as expenses in the period when the employees have performed services to Qlife. Post-employment benefits are funded with defined contribution plans. Plans where Qlife’s obligation is limited to the agreed fee are defined as defined contribution plans. For those plans, the size of the employee benefit depends on the fees paid by Qlife to the plan and the return on that capital, thus the employee takes the actuarial risk and the investment risk. Qlife’s obligation for fees to defined contribution plans are recognized as expenses in the period when the employees have performed services to Qlife. Income taxes The item ”Income tax expense” in the income statement comprises current and deferred income tax. The current tax expense is the expected tax expense on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. Deferred tax assets and liabilities are recognized, using the balance sheet method, for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences arising on initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit. Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted at the reporting date. Deferred tax assets are recognized only to the extent that there is a high probability that future taxable profits will be available against which the temporary differences, tax losses carry forward and unused tax credits can be utilized. Intangible assets Separate acquisitions Separately acquired intangible assets are recognized at cost less accumulated amortization and impairment. The assets are amortized on a straight-line basis over the estimated useful life of the asset. Current estimated useful life for patents is 5 years. Internally generated intangible assets Product development is divided into a research phase and a development phase. All expenses during the research phase are recognized as expenses in the income statement as they are incurred. All expenditures are capitalized if the following conditions are fulfilled: It is technically feasible to complete the intangible asset so that it will be available for use or sale • The group has the intention of completing the asset • The group has the ability to use or sell the asset • It is probable that the asset will generate future economic benefits • The group has the adequate technical, financial and other resources to complete the development and to use or sell the intangible asset • The expenditure attributable to the asset can be reliably measured Capitalized directly attributable expenses include employee expenses, expenses for services and direct material. At each balance sheet date internally generated intangible assets are recognized at cost less accumulated amortization and impairment. Amortization begins when the asset can be taken into use. Capitalized expenses are amortized on a straight-line basis over an estimated useful life of five years. Reassessment of useful life Estimated useful lives and amortization methods are reassessed when there is an indication of a change since the estimate on the prior balance sheet date. The effect of changes in estimates are recognized forward-looking. Amortization begins when the asset can be taken into use. Removal from the balance sheet An intangible asset is removed from the balance sheet when the asset is scrapped or sold or when no future economic advantages are expected from the use of the asset. Any profit or loss that arises upon removal of the asset from the balance sheet is the difference between consideration received, after deduction of direct selling expenses, and the carrying amount of the asset. This profit or loss is recognized as other operating income or other operating expenses. Tangible assets Tangible assets are recognized at cost less accumulated depreciation and impairment. Cost includes all expenditure directly attributable to bringing the asset to the location and condition necessary for its intended use. The cost also includes the estimated cost of its dismantlement, removal or restoration. Additional expenses that qualify for asset recognition are added to the carrying amount of the asset. Expenses for repairs are recognized as expenses as they are incurred. Tangible assets are depreciated on a straight-line basis over the estimated useful life of the asset. Depreciation begins when the asset can be taken into use. Tangible assets of the group consist of equipment and have an estimated useful life of 5-10 years. Any profit or loss from sales of a tangible asset is recognized as Other operating income or Other operating expenses. Notes
Page 24
Qlife Holding AB I Interim report Q2 April- June 2026 24 Impairment of intangible and tangible assets At each balance sheet date, the group analyzes the carrying amounts of tangible and intangible assets to determine whether there is any indication of impairment. If any such indication exists, the recoverable amount is calculated in order to determine the amount of an impairment. If the recoverable amount for an individual asset cannot be determined, the recoverable amount is calculated for the cash- generating unit to which the asset belongs. Development not yet taken into use are not amortized but tested for impairment annually irrespective of any indications of impairment. The recoverable amount is the highest of fair value less costs of disposal and the value in use of the asset. Fair value less costs of disposal is the price expected to be received in a transaction less costs directly attributable to the transaction. When determining value in use future cash flows are discounted to present value using a discount rate before tax reflecting current market conditions of the time value of money and the risks associated with the asset. At each balance sheet date, the group estimates whether a previous impairment is no longer motivated. If this is the case, the impairment is reversed. A reversal of an impairment is recognized in the income statement. The group as a lessee The group has lease agreements for premises and production equipment. The group recognizes all lease agreements in the balance sheet as a lease liability for the obligation to pay future fixed lease payments, and a right-of-use asset reflecting the right to use an underlying asset. The lease liability is recognized at amortized cost using the effective interest rate method which distributes lease payments between repayment of the lease liability and interest expense. Lease liabilities are recognized as the present value of all remaining lease payments in the balance sheet and includes the following lease payments: • Fixed payments • Variable payments that depend on an index or a rate • The exercise price of a purchase option if the group is reasonably certain to exercise that option The lease liability is measured as the lease payments discounted with the incremental borrowing rate of the lessee. To calculate the lease liability, the lease payments are discounted with the implicit interest in the lease agreement. If this interest rate cannot be easily determined, the lessee’s marginal borrowing rate is used. The right-of-use asset is measured at cost and recognized at the amount of the lease liability with adjustment for initial expenses and expenses for restoring the lease asset according to the lease agreement. Right-of-use assets are depreciated on a straight-line basis over the shortest of the useful life of the asset or the lease term. If the group is reasonably certain to exercise a purchase option, the right-of- use asset is depreciated over the useful life of the underlying asset. The group has chosen not to report in the statement of financial position leasing agreements for which the underlying asset is of low value or with a leasing period (including an extension period that the group is reasonably sure is expected to utilize) of less than 12 months. The group reports leasing fees that are covered by the exemption rules as a leasing cost on a straight-line basis over the leasing period. The group has chosen to apply the practical solution that gives a lessee the opportunity to choose not to separate leasing components from non-leasing components for premises leases and instead report each leasing component and non-leasing component as a single leasing component. Inventories Inventories have been valued according to the lowest value principle, i.e. at the lower of acquisition value and net sales value. The acquisition value consists of direct cost of goods, direct salary, and attributable indirect manufacturing costs (based on normal manufacturing capacity). The acquisition value for individual items in the inventory is distributed based on weighted average costs calculated according to the manufacturing price calculation. In determining the acquisition value, the first-in first-out principle has been applied. The net sales value consists of estimated sales value less estimated sales cost. The Groups financial instruments are composed of: • Accounts receivables • Cash and cash equivalents • Bank loans and other loans • Other long term liabilities • Accounts payables Financial assets Financial assets at amortized cost Assets in this category primarily arise from the sales of goods and services to customers but also include other types of financial assets where the objective is to hold the assets to collect the contractual cash flows and these cash flows are exclusively payments of principal and interest. These assets are initially recognized at fair value plus costs of transaction directly attributable to the acquisition, and are carried at amortized cost in subsequent periods, using the effective interest rate method. Impairment Impairment requirements for account receivables are reported based on the simplified approach using the expected credit losses for the entire remaining life of the contract. To calculate the credit loss reserve on accounts receivable, the group uses a matrix. The historical loss rates are adjusted to reflect current and forward-looking information that affects customers’ ability to pay the claim. For account receivables, which are reported net, provisions are reported in a separate reserve for feared customer losses, and the cost is reported as a sales cost in the income statement. Upon confirmation that the accounts receivable will not be payable by the customer, the gross value of the asset is depreciated against the associated reserve. The group has historically reported low customer losses, customer loans are relatively short-term, and the company has relatively few unpaid outstanding overdue accounts receivable. The credit risk is assessed as low. Cash and cash equivalents Cash and cash equivalents include cash, bank deposits, other short- term high-liquidity investments with original maturities of three months or less. Cash and cash equivalents in the cash flow analysis also include, for example, overdrafts on bank accounts and overdraft facilities. However, these are reported as current liabilities in the consolidated balance sheet. Financial liabilities Notes
Page 25
Qlife Holding AB I Interim report Q2 April- June 2026 25 The financial liabilities are classified and valued as liabilities valued at accrued acquisition value. Financial liabilities include the following items: • Bank loans and other loans are initially reported at fair value less transaction costs directly attributable to the instrument’s issue. These interest-bearing liabilities are then measured at amortized cost using the effective interest method, which ensures that the interest expense is calculated based on a fixed interest rate on the reported amount of the liability in the balance sheet. The reported effective interest rate includes initial transaction costs and any premiums to be paid upon redemption as well as interest or coupons that are paid while the debt is outstanding. • Accounts payable are obligations to pay for goods or services that have been acquired in the current accounts. Accounts payable are classified as current liabilities if they fall due within a year or earlier (or during the normal business cycle if this is longer). Provisions Provisions are recognized when the group has a present obligation as a result of a past event and it is likely that payments will be required to settle the obligation. One condition is that it is possible to make a reliable estimate of the amount to be paid. The provisions are calculated as the present value of the amounts expected to be paid to settle the obligation. In the calculation, a discount rate before tax is used, reflecting a current valuation of the time value of money and of the risks associated with the provision. Any increase in the provision caused by the passage of time is accounted for as a financial expense. Contingent liabilities The group provides information on contingent liabilities if there is a possible commitment that is confirmed only by several uncertain future events and it is not probable that an outflow of resources is required or that the size of the commitment cannot be determined with sufficient certainty. Contingent assets The group provides information on contingent assets as a result of events that have occurred, the occurrence of which will only be confirmed by the occurrence or absence of one or more uncertain future events, which are not entirely within the company’s control (see note 5). Statement of cash flows The group prepares its statement of cash flows using the indirect method, whereby adjustments have been made for transactions not generating any payments during the reported period. Adjustments have also been made for cash flows of revenue and expenses belonging to investment or financing activities. Earnings per share Basic earnings per share are calculated by dividing the profit or loss attributable to shareholders of the parent company by the weighted average number of ordinary shares outstanding during the period. For the periods reported there were no potential ordinary shares requiring an adjustment for dilution. Note 3 Important sources of uncertainty in estimates Important sources of uncertainty in estimates The group’s financial reports are prepared in accordance with IFRS. This means that the preparation of financial statements and the application of accounting principles are often based on estimates and assumptions that are considered reasonable and well balanced at the time the assessment is made. However, with other judgments, assumptions and estimates, the result may be different, and events may occur that may require a material adjustment to the carrying amount of the relevant asset or liability. Below are the most important areas where estimates and judgments have been made and which are deemed to have the greatest impact on the financial reports. Intangible assets The group conducts development activities. An intangible asset that arises through development, so-called capitalized development cost for own account, must only be taken up as an asset in the balance sheet if all conditions in IAS 38 are met. The principle is described in more detail in note 2. For each development project, the group’s management team continuously assesses whether there are condi- tions for selling the finished product and whether there is technical competence and financial resources to complete the asset so that it will be available for use or sale and thereby generate probable future financial benefits. There are no indications of a need for impairment as of 30 June 2026. Valuation of inventory Inventories are valued at the lower of acquisition value and net sales value according to the principle described in note 2. Note 4 Financial risk management Financial risk The group is exposed to financial risks in the entire operation. The board has overall responsibility for managing financial risks and internal controls related to financial transactions. Financial risks and transactions are managed centrally by the parent company through the group’s CFO and CEO, according to policies determined by the board. The financial risks are managed, assessed and reported regularly to the board. The purpose of managing the financial risks is to minimise the risks of negative impact on the group’s results. The most important market and financial risks are described below. Currency risk Currency risk refers to the risk that fair value or future cash flows fluctuate as a result of changing exchange rates. The exposure to currency risk mainly stems from payment flows in foreign currency, so- called transaction exposure, and from the translation of balance sheet items in foreign currency to the group’s presentation currency, which is Swedish kronor, so-called balance sheet exposure. The group’s outflow mainly consists of DKK and EUR, while the group’s inflow mainly consists of EUR and SEK. The group is thus affected by changes in these exchange rates. Funding risk Qlife has historically generated negative results and the company’s cash flows from operating activities have not been sufficient to meet the company’s capital requirements. The generated cash flow is estimated to remain negative until Qlife enters into significant agreements for the sale of existing and new products that the company can market. Management and board follow the Notes
Page 26
Qlife Holding AB I Interim report Q2 April- June 2026 26 development of the financial situations closely in order to be able to recognize and take measures against future financial and cash liquidity risk. Future financing needs depend on whether the group succeeds in entering into new partner and business agreements and the market’s reception of current and future potential products. It should be noted in particular that medical device development is a resource-intensive and time-consuming activity that requires extensive work in the form of research and development, including lengthy and costly clinical studies and procedures to obtain regulatory approvals before a final product can be marketed towards the clinical market. It may therefore take a long time before the company’s products can be sold commercially to the clinical market and generate ongoing cash flow. A continued lack of positive and steady operating income streams may mean that Qlife will be forced to raise additional capital in the future. Access to additional financing is affected by a number of factors such as market conditions, the general availability of credit and Qlife’s creditworthiness and credit capacity. Disruptions and uncertainty in the capital and credit markets can also limit access to the capital required to run the business. If in the future Qlife fails to acquire the necessary capital on terms reasonable to the company, Qlife’s development, manufacturing and sales activities as well as cash flow/liquidity may be adversely affected. To the extent that Qlife obtains additional financing by issuing shares or share-related instruments, the company’s shareholders will be affected by dilution to the extent that such new issues occur with a deviation from the shareholders’ preferential rights. The group strives to minimize potential adverse effects of the unpredictability of the financial markets in which the group operates. In addition to what is explained below, there are currently no significant financial risks. Liquidity risk/Financing risk Liquidity risk refers to the risk that the group will have problems fulfilling its commitments regarding its financial liabilities. Financing risk refers to the risk that the group cannot raise sufficient financing at a reasonable cost. The group finances its operations to a significant extent with new issues. The group manages capital based on financing needs for efficient continued development of products and their commercialization. Liquidity risk management is based on maintaining sufficient liquid funds. The liquidity risk is managed through ongoing liquidity planning. This follow-up is reported to Notes the board, where the outcome and forecast are compared with the budget that is drawn up and approved by the board every year. The Group’s objective regarding the capital structure is to ensure financing of the company’s development and business plan so that it can generate returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure that minimizes capital costs. The company’s current operations are to a great extent in a risky and capital-intensive period, and an effective risk assessment combines the group’s business opportunities and results with the shareholders’ and other stakeholders’ demands for sustainable profitability, stable long-term value development and control. The group’s profitability depends on the quality and value of generated development results. The value and quality of the R&D activities are continuously evaluated by company management and the board.
Page 27
Qlife Holding AB I Interim report Q2 April- June 2026 27 Note 5 Composition of income 2021 2022 2023 2024 2025 2026 Sales revenue (kSEK) Q1-Q4 Q1-Q4 Q1-Q4 Q1-Q4 Q1 Q2 Q3 Q4 Q1 Q2 Sweden 13,642 14,351 62 - 3 - - - - - Finland 3,981 3,985 - - - - - - - - Denmark 21,109 30 - - - - - - 728 Other countries 881 449 152 50 103 104 65 49 22 0 Total Sales 39,613 18,785 244 50 106 104 65 49 22 728
Page 28
Qlife Holding AB I Interim report Q2 April- June 2026 28 qlifeholding.com